Results 141 to 150 of about 2,131 (185)

Fremanezumab for the preventive treatment of migraine in adults

Expert Review of Clinical Pharmacology, 2019
Introduction: The Calcitonin Gene-Related Peptide (CGRP) has been implicated in migraine pathophysiology due to its role in neurogenic inflammation and transmission of trigeminovascular nociceptive signal. New molecules targeting CGRP and its receptor have been developed as migraine-specific preventative treatments. Fremanezumab (or TEV-48,125, LBR-101)
Luana Lionetto, Martina Guglielmetti, Martina Curto   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Effectiveness of fremanezumab treatment in patients with migraine headache

Pain Medicine
Abstract Objective To evaluate the efficacy and safety of fremanezumab for migraine prevention. Design Retrospective, single-center, real-world study.
Shoji Kikui, Hanako Sugiyama, Yoshihiro Kashiwaya   +2 more
exaly   +3 more sources

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry

Journal of Clinical Medicine, 2023
Objective: To define, in a real-world population of patients with high-frequency episodic (HFEM) or chronic migraine (CM), the predictive role of socio-demographic or phenotypic profiling of responders to fremanezumab.
Georgia Xiromerisiou, Michail Vikelis, Andreas A Argyriou   +2 more
exaly   +2 more sources

A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects

Cephalalgia, 2018
Objectives The primary and secondary objectives of this phase 1 study were to evaluate the pharmacokinetic profile, safety, and immunogenicity of fremanezumab subcutaneous (sc) doses tested in phase 2 and 3 trials (225 mg, 675 mg and 900 mg) following ...
Paul P Yeung, Michele Rasamoelisolo, Orit Cohen-Barak   +2 more
exaly   +2 more sources

Fremanezumab for the preventive treatment of migraine

Expert Opinion on Biological Therapy, 2019
Introduction: The recent approval of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway introduced the first preventive treatments for migraine that were specifically designed to target the underlying pathophysiology of the disease.
Stephen D, Silberstein, Joshua M, Cohen, Paul P, Yeung   +2 more
openaire   +2 more sources

Real-World Lessons with Fremanezumab as the Third Available CGRP Monoclonal Antibody in a Third-Level Hospital: Focus on the Factors Predicting Response [PDF]

Journal of Clinical Medicine
Background: Fremanezumab was the third CGRP antibody available in our hospital. This examination of our experience with fremanezumab is focused on identifying the predictors of response.
Julio Pascual, Vicente González-Quintanilla, Gabriel Garate   +2 more
exaly   +2 more sources

From LBR-101 to Fremanezumab for Migraine

CNS Drugs, 2018
Calcitonin gene-related peptide (CGRP) is a neuropeptide of importance in migraine pathogenesis. Its central role in migraine was proven pharmacologically by the development of CGRP receptor antagonists. Monoclonal antibodies targeting CGRP or its receptor are effective in the preventive treatment of episodic and chronic migraine and are considered ...
Marcelo E, Bigal, Alan M, Rapoport, Stephen D, Silberstein, Sarah, Walter, Richard J, Hargreaves, Ernesto, Aycardi   +5 more
openaire   +2 more sources

Fremanezumab Autoinjector Pen for the Prevention of Migraine

Therapeutic Delivery, 2021
Ajovy (fremanezumab, Teva Pharmaceuticals, Israel) is a fully humanized monoclonal antibody that selectively binds both isoforms of the calcitonin gene-related peptide. Calcitonin gene-related peptide is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events in migraine.
openaire   +2 more sources

Fremanezumab

Reactions Weekly
Fremanezumab, fully humanized antibody from a group of calcitonin gene‑related peptide (CGRP) antagonists, is indicated as prophylaxis in patients suffering from migraine at least 4 days a month. It is administered subcutaneously once a month or once every three months.
openaire   +3 more sources